and subsequent dosing guided by serial SU measurements to achieve a target SU, over a fixed-dose ULT strategy, is strongly recommended for all patients receiving ULT. Achieving and maintaining an SU target of <6 mg/dl over the use of no target is strongly recommended for all patients receiving ULT. We recommend using a treat-to-target management strategy to optimize patient outcomes by achieving and maintaining an SU target of <6 mg/dl rather than using a fixed-dose strategy (Table 3 2